Drugs最新文献_第2页

Retraction Note: Progesterone Treatment to Prevent Preterm Birth. 注：黄体酮治疗预防早产。

IF 14.4 1区医学

Drugs Pub Date : 2025-10-01 DOI: 10.1007/s40265-025-02230-9

Paul J Meis, Alicia Aleman

引用次数: 0

Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management. 临床使用每周一次胰岛素Icodec：将临床试验数据转化为糖尿病管理的实用指导。

IF 14.4 1区医学

Drugs Pub Date : 2025-10-01 Epub Date: 2025-08-13 DOI: 10.1007/s40265-025-02201-0

Athena Philis-Tsimikas, Jens Aberle, Harpreet Bajaj, Ildiko Lingvay, Yiming Mu, Shehla Shaikh, André Vianna, Hirotaka Watada, Stefano Del Prato

{"title":"Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management.","authors":"Athena Philis-Tsimikas, Jens Aberle, Harpreet Bajaj, Ildiko Lingvay, Yiming Mu, Shehla Shaikh, André Vianna, Hirotaka Watada, Stefano Del Prato","doi":"10.1007/s40265-025-02201-0","DOIUrl":"10.1007/s40265-025-02201-0","url":null,"abstract":"Insulin icodec (icodec) is a first-in-class once-weekly basal insulin approved for the treatment of adults with type 1 diabetes (T1D) and type 2 diabetes (T2D). Healthcare professionals (HCPs) may benefit from clear and practical guidance on translating the use of icodec from a controlled clinical trial setting into real-world clinical practice to ensure its appropriate implementation. Here, we primarily review the available evidence for icodec in T2D to provide evidence-based clinical recommendations and expert opinions to guide the use of icodec in a clinical setting. The pharmacology of icodec is summarized, along with an overview of the results from the ONWARDS 1-6 clinical trials (NCT04460885, NCT04770532, NCT04795531, NCT04880850, NCT04760626, NCT04848480). Key guidance on the practical use of icodec, including treatment initiation, switching to icodec from a once- or twice-daily basal insulin, switching from icodec back to a daily basal insulin, and dose titration, is provided. Icodec usage in special populations and practical situations (e.g., elderly and pediatric individuals, hepatic and renal impairment, hospitalized individuals, and those who are pregnant or planning pregnancy) is discussed. Considerations for glucose monitoring and management, as well as co-administration of icodec with other non-insulin glucose-lowering medications, are provided. Finally, we also briefly summarize the available evidence on icodec use in individuals with T1D, although the primary focus of this review is on its use in T2D. This review provides a comprehensive information resource for HCPs regarding the use of icodec in clinical practice.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"1253-1268"},"PeriodicalIF":14.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tirofiban in Acute Ischemic Stroke: Mechanistic Rationale, Clinical Advances, and Emerging Therapeutic Strategies. 替罗非班治疗急性缺血性卒中：机制原理、临床进展和新出现的治疗策略。

IF 14.4 1区医学

Drugs Pub Date : 2025-10-01 Epub Date: 2025-08-22 DOI: 10.1007/s40265-025-02222-9

Yuye Jiang, Wenrui Huang, Yiyang Zhang, QiuHong Ji

{"title":"Tirofiban in Acute Ischemic Stroke: Mechanistic Rationale, Clinical Advances, and Emerging Therapeutic Strategies.","authors":"Yuye Jiang, Wenrui Huang, Yiyang Zhang, QiuHong Ji","doi":"10.1007/s40265-025-02222-9","DOIUrl":"10.1007/s40265-025-02222-9","url":null,"abstract":"Tirofiban is a selective inhibitor of the glycoprotein IIb/IIIa receptor that reversibly prevents platelet aggregation and clot formation-processes central to the development and progression of ischemic stroke. Its use has been widely studied in both laboratory and clinical settings, particularly as an early intervention, a rescue option after failed mechanical thrombectomy, and in combination with clot-dissolving therapies. Emerging evidence supports tirofiban's role in preventing stroke progression, especially in high-risk groups such as older adults, women around menopause, patients with diabetes, liver or kidney dysfunction, and those who are pregnant. The drug has generally shown good safety and effectiveness in promoting blood flow restoration and improving long-term recovery. However, the most effective dosing, treatment scenarios, and patient profiles remain uncertain. Given its strong antiplatelet action and potential protective effects on brain tissue, tirofiban continues to gain interest as a treatment for acute ischemic stroke. This review summarizes key studies published since 2018, based on a structured literature search of PubMed, Embase, and Web of Science through May 2025, with the goal of guiding future research and improving clinical integration.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"1269-1287"},"PeriodicalIF":14.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapy for Autoimmune Pulmonary Alveolar Proteinosis. 自身免疫性肺泡蛋白沉积症的药物治疗

IF 14.4 1区医学

Drugs Pub Date : 2025-10-01 Epub Date: 2025-08-27 DOI: 10.1007/s40265-025-02228-3

Stéphane Jouneau, Pierre Chauvin, Mathieu Lederlin, Benoît Painvin, Mallorie Kerjouan

{"title":"Pharmacotherapy for Autoimmune Pulmonary Alveolar Proteinosis.","authors":"Stéphane Jouneau, Pierre Chauvin, Mathieu Lederlin, Benoît Painvin, Mallorie Kerjouan","doi":"10.1007/s40265-025-02228-3","DOIUrl":"10.1007/s40265-025-02228-3","url":null,"abstract":"Pulmonary alveolar proteinosis is suspected when a \"crazy paving\" pattern is observed on a chest CT scan. This diagnosis is confirmed by the presence of eosinophilic extracellular material that shows positive staining with Periodic Acid Schiff on bronchoalveolar lavage samples. The autoimmune form of pulmonary alveolar proteinosis is confirmed by detecting anti-granulocyte-macrophage colony-stimulating factor antibodies in the patient's serum. The historical first-line treatment for autoimmune pulmonary alveolar proteinosis is whole lung lavage, which should only be performed in expert centers. It remains the preferred treatment for patients experiencing respiratory failure, especially at the time of diagnosis. Inhaled granulocyte-macrophage colony-stimulating factor supplementation with molgramostim or sargramostim is now considered a first-line treatment in the international guidelines for autoimmune pulmonary alveolar proteinosis, following the positive results of recent randomized placebo-controlled studies. Rituximab and plasmapheresis can be prescribed as third- and fourth-line treatments, respectively. Lung transplantation may be considered for eligible patients experiencing terminal respiratory failure. A deeper understanding of the pathogenesis of autoimmune pulmonary alveolar proteinosis has opened up new therapeutic avenues, such as the use of PPARγ agonists or statins.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"1193-1206"},"PeriodicalIF":14.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrasentan: First Approval. 阿特拉森人：第一次批准。

IF 14.4 1区医学

Drugs Pub Date : 2025-10-01 Epub Date: 2025-08-04 DOI: 10.1007/s40265-025-02208-7

Susan J Keam

引用次数: 0

Linvoseltamab: First Approval. Linvoseltamab：首次批准。

IF 14.4 1区医学

Drugs Pub Date : 2025-10-01 Epub Date: 2025-08-29 DOI: 10.1007/s40265-025-02207-8

Arnold Lee

引用次数: 0

Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms. 绝经期血管舒缩症状的药物治疗进展

IF 14.4 1区医学

Drugs Pub Date : 2025-09-30 DOI: 10.1007/s40265-025-02231-8

Stephanie Young Moss, Angie Lee, James A Simon

{"title":"Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms.","authors":"Stephanie Young Moss, Angie Lee, James A Simon","doi":"10.1007/s40265-025-02231-8","DOIUrl":"https://doi.org/10.1007/s40265-025-02231-8","url":null,"abstract":"Vasomotor symptoms (VMS) are considered the cardinal symptoms of menopause, affecting up to 80% of American women at some point during the menopausal transition. VMS, particularly if they are moderate to severe, frequent, or cause sleep disturbances, can have a negative impact on a woman's quality of life, physical and mental health, and professional life. Furthermore, VMS have been associated with negative health outcomes, including an increased risk of coronary heart disease and cognitive impairment. Menopausal hormonal therapy (MHT) is supported by level 1 evidence and can address many of the negative impacts associated with menopause, including VMS. However, not all women can take MHT (owing to having contraindications to their use) or choose not to take MHT. In addition to MHT, non-hormonal therapy options, which include neurokinin (NK)-targeted therapies, are also available. Fezolinetant (NK3 receptor antagonist) and the newly approved elinzanetant (NK1 and NK3 receptor antagonist) are non-hormonal treatment options approved for the treatment of VMS associated with menopause. These approvals expand the treatment options for women. A number of investigational agents are currently in phase 2 trials for potential future use for VMS; these include Q-122, PhytoSERM, NOE-115, GS1-144, and HS-10384. In this review, we highlight the recent advancements in our understanding of the pathophysiology of VMS and consider the current, new, and investigational treatment options for the treatment of VMS.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":""},"PeriodicalIF":14.4,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Toxicities of Immune Checkpoint Inhibitors. 免疫检查点抑制剂的长期毒性。

IF 14.4 1区医学

Drugs Pub Date : 2025-09-30 DOI: 10.1007/s40265-025-02243-4

Preethy E Abraham, Douglas B Johnson

{"title":"Long-Term Toxicities of Immune Checkpoint Inhibitors.","authors":"Preethy E Abraham, Douglas B Johnson","doi":"10.1007/s40265-025-02243-4","DOIUrl":"https://doi.org/10.1007/s40265-025-02243-4","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) produce often durable responses in many cancer types but are associated with autoimmune-like toxicities. These immune-related adverse events (irAEs) occur in multiple organ systems and often improve with steroids or therapy cessation. However, many irAEs have either partial or no improvement, leading to residual sequelae even after ICI discontinuation. Chronic irAEs, often defined as irAEs lasting > 3 months, may occur in up to 40-50% of patients treated with ICI therapy and have a wide range of manifestations, severity, and duration. These chronic events likely stem from either ongoing inflammation or sequalae of prior inflammatory-mediated damage. IrAEs impacting the endocrine glands and joints have particularly high rates of chronicity, while chronic events impacting the gastrointestinal (GI) tract, liver, and lungs are less common. In this review, we discuss updated studies surrounding chronic irAEs, providing an overview, followed by organ-specific considerations and consideration of future directions. Key challenges for the field include characterizing the chronic impact of irAEs, developing better treatment or prevention strategies (one possible solution being anti-cytokine therapy), and identifying which patients have active inflammation.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":""},"PeriodicalIF":14.4,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mazdutide: First Approval. Mazdutide：首次批准。

IF 14.4 1区医学

Drugs Pub Date : 2025-09-30 DOI: 10.1007/s40265-025-02249-y

Matt Shirley

引用次数: 0

Ifupinostat: First Approval. Ifupinostat：首次批准。

IF 14.4 1区医学

Drugs Pub Date : 2025-09-30 DOI: 10.1007/s40265-025-02248-z

Simon Fung

引用次数: 0